Navigation Links
Nature's Bioceuticals Close to Finalizing Strategic Transaction in One of the Largest Drug Markets
Date:11/2/2011

etic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements.

Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: investors@naturesbioceuticals.com

SOURCE Nature's Bioceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
2. Natures Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula
3. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
4. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
5. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
6. Graphenes quantum leap takes electronics a step closer
7. Avisena Closes $2.5 Million of Debt Capital By Square 1 Bank
8. Cephalon to Release Second Quarter 2011 Earnings Results After the Market Close on August 2, 2011
9. Nanoengineers invent new biomaterial that more closely mimics human tissue
10. UCLA researchers now 1 step closer to controlled engineering of nanocatalysts
11. Summer Street Research Partners Closes Financing for ImmunoCellular Therapeutics, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Follow ... level of each type of cholesterol carrier or lipoprotein ... presence of excessive cholesterol levels in the body, especially ... condition to heart attack and other cardiovascular disorders. Cardiovascular ... therefore testing for cholesterol levels on a regular basis, ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... 2014 FemCap Inc., www.femcap.com  an innovator ... of a patent No: US, 8,795,248 B2 dated Aug. ... FDA clearance in the U.S., 510(K) K121857, medical device ... patent is related to its menstrual cup with a ... is releasing FemmyCycle Teen, a third menstrual cup to ...
(Date:9/30/2014)... 2014 Lyme Research Alliance ... disease research at universities, today announced the awarding of ... identification, treatment and cure for Lyme and other tick-borne ... most applications in its history—over 20 grant proposals—a 100 ... were pleased to receive so many solid applications from ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... 29 Dawson James Securities, a,full- service investment ... coverage on CryoCor, Inc. (Nasdaq: CRYO ) ... price target of $6.00. John M.,Putnam, Sr. VP-Medical ... CryoCor,s recently FDA-approved cryoablation,system for atrial flutter and ...
... Pharmaxis,(ASX: PXS, Nasdaq: PXSL) today announced that its ... of people with bronchiectasis has met its two,primary ... Data from the 362 subject study demonstrated ... 12 weeks of treatment with Bronchitol,as assessed by ...
... Fund is Largest and First of its Kind in ... support initiatives,that enhance patient safety and quality of care, ... million to fund new and innovative programs,at hospitals, health ... is the largest and first of its kind given ...
Cached Biology Technology:Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 2Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 3
(Date:9/29/2014)... at home should use ventilation when cooking with a ... after a new study showed an association between gas ... bronchitis. , "In homes where a gas stove was ... is higher than in homes where a gas stove ... professor in the College of Public Health and Human ...
(Date:9/29/2014)... get a bad rap, and understandably so. The grain-of-rice-sized ... of millions of acres in the Western U.S. and ... to popular belief, these pests may not be to ... recently swept through the region. Instead, weather and topography ... fires than these bark-boring beetles. , New research led ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
Breaking Biology News(10 mins):Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... Today, on behalf of the Association for Molecular Pathology ... US Food and Drug Administration,s (FDA) meeting on "Ultra ... to Assess Analytical Validity." As they begin developing their ... officials on many important considerations for evaluating analytical validity. ...
... Sea will promote fish stock recovery and increase fishermen,s incomes, ... York., In the North Sea up to 75 per cent ... result that many fisheries are now badly overfished. In comparison, ... and their fisheries are now some of the most prosperous ...
... LOS ALAMOS, New Mexico, June 22, 2011 Los Alamos ... 2011 R&D100 Awards. Recognized as the "Oscars of Invention" ... 100 proven technological advances of the past year. The ... specific nucleic acids, a spacer fluid for oil wells ...
Cached Biology News:AMP comments at FDA meeting on next-generation sequencing 2Discards ban 'will boost fisheries', says new research 2Los Alamos National Laboratory earns 3 R&D 100 Awards 2Los Alamos National Laboratory earns 3 R&D 100 Awards 3
... latest entry in the Biomek line. With an,up-to-date ... robustness, it can meet the needs of just ... either one or two pipetting pods. With its ... standard for flexible laboratory solutions to meet your ...
... The Biomek FX provides complete ... applications. With 96-, 384-, ... heads in either single or ... FX offers maximum speed and ...
... trays are disposable trays that ... that have been blotted onto ... eight 10.5 cm x 5 ... cut from blotted membrane and ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
Biology Products: